Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Acta Trop ; 232: 106498, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35513072

RESUMEN

Rift Valley fever (RVF) is an emerging transboundary, mosquito-borne, zoonotic viral disease caused by a single serotype of a virus belonging to the Phenuiviridae family (genus Phlebovirus). It is considered an important threat to both agriculture and public health in endemic areas, because the virus, transmitted by different mosquito genera, leads to abortions in susceptible animal hosts especially sheep, goat, cattle, and buffaloes, resulting in severe economic losses. Humans can also acquire the infection, and the major sources are represented by the direct contact with infected animal blood, aerosol, consumption of unpasteurized contaminated milk and the bite of infected mosquitoes. Actually, the EU territory does not seem to be exposed to an imminent risk of RVFV introduction, however, the recent outbreaks in a French overseas department and some cases detected in Turkey, Tunisia and Libya, raised the attention of the EU for a possible risk of introduction of infected vectors. Thus, there is an urgent need to develop new therapeutic and/or preventive drugs, such as vaccines. In our work, we studied the immunogenicity of an inactivated and adjuvanted vaccine produced using a Namibian field strain of RVF virus (RVFV). The vaccine object of this study was formulated with Montanide Pet Gel A, a polymer-based adjuvant that has been previously reported for its promising safety profile and for the capacity to elicit a strong immune response. The produced inactivated vaccine was tested on six sheep and the level of IgM and IgG after the immunization of animals was evaluated by a commercial competitive ELISA, in order to assess the immunogenicity profile of our vaccine and to evaluate its potential use, as an alternative to the attenuated vaccines commercially available, in case of Rift Valley fever epidemic disease on EU territory. Following the administration of the second dose, 35 days after the first one, all animals seroconverted.


Asunto(s)
Culicidae , Fiebre del Valle del Rift , Virus de la Fiebre del Valle del Rift , Vacunas Virales , Adyuvantes Inmunológicos , Animales , Bovinos , Aceite Mineral , Mosquitos Vectores , Fiebre del Valle del Rift/epidemiología , Ovinos , Vacunas de Productos Inactivados , Vacunas Virales/efectos adversos , Zoonosis/prevención & control
2.
PLoS One ; 10(2): e0117433, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25643159

RESUMEN

The aim of this study was to shed light in to the complexity of the ovine colostrum proteome, with a specific focus on the low abundance proteins. The ovine colostrum is characterized by a few dominating proteins, as the immunoglobulins, but it also contains less represented protein species, equally important for the correct development of neonates. Ovine colostrum, collected immediately after lambing, was separated by 1D SDS-PAGE. Proteins bands were digested with trypsin and the resulting peptides were analyzed by LC-MS/MS. On the basis of the Swiss-Prot database, a total of 343 unique proteins were identified. To our knowledge, this study represents the most comprehensive analysis of ovine colostrum proteome.


Asunto(s)
Calostro/metabolismo , Proteómica , Ovinos/metabolismo , Animales , Femenino , Regulación de la Expresión Génica , Ontología de Genes , Lactancia , Proteínas de la Leche/genética , Proteínas de la Leche/metabolismo , Embarazo , Ovinos/genética , Ovinos/crecimiento & desarrollo , Ovinos/fisiología , Proteína de Suero de Leche
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA